Navigation Links
AEterna Zentaris Receives US$10 Million from Institutional Investors
Date:6/24/2009

QUEBEC CITY, June 24 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, announced today that it has completed its previously announced registered direct offering of US$10 million of units comprised of common shares and common share purchase warrants to certain institutional investors. AEterna Zentaris received net proceeds of approximately US$9.25 million after deducting placement agent fees and other offering expenses. All of the common shares and warrants were offered pursuant to an effective shelf registration statement. Proceeds from the transaction will be used for general corporate purposes, including clinical development of the Company's leading oncology and endocrinology compounds.

Dr. Juergen Engel, Ph. D., President and CEO of AEterna Zentaris stated, "We are very pleased with this vote of confidence from targeted specialized institutional investors. In addition, completing this financing provides us with additional funds that will help us to further strengthen our promising oncology pipeline."

As of June 24, 2009 and after issuing 5,319,149 common shares at the closing of the offering, the Company had 58,506,619 common shares issued and outstanding.

A shelf registration statement relating to the common shares and warrants issued in the offering (and the common shares issuable upon exercise of the warrants) has been filed with the Securities and Exchange Commission (the "SEC") and has been declared effective. A prospectus supplement relating to the offering was filed with the SEC. Copies of the prospectus supplement and accompanying prospectus may be obtained directly from AEterna Zentaris Inc., 1405 du Parc-Technologique Boulevard, Quebec City, Canada G1P 4P5. This announcement is neither an offer to sell nor a solicitation of an of
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Md., July 29, 2014  United Therapeutics Corporation ... its financial results for the second quarter ... growth shows that our medicines are reaching ... arterial hypertension (PAH)," said Martine Rothblatt, Ph.D., ... "The commercial launch this quarter of our ...
(Date:7/29/2014)... San Diego, CA (PRWEB) July 29, 2014 ... added to Pipette.com’s centrifugation product selection. Eppendorf 5427 R ... reverse engineering, and DNA – it is targeted towards ... the Eppendorf Centrifuge 5427 R as it compliments their ... as their Eppendorf line of microcentrifuge tubes, PCR tubes, ...
(Date:7/29/2014)... 2014 White papers by Clinovo ... based eClinical technologies, have been published by leading pharmaceutical ... a long line of white papers by Clinovo to ... Science Leader, Pharmaceutical Online, and OpenHealthNews. , At the ... by CTO Marc Desgrousilliers, 'The Five Essentials of ...
(Date:7/28/2014)... materials using light, developed by researchers at the University ... often considered the realm of science fiction, such as ... starships won,t be a reality for quite some time, ... with building blocks a few billionths of a metre ... light flies through them, and works on large chunks ...
Breaking Biology Technology:United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13International Pipette Distributor, Pipette.com Announces the Addition of the Eppendorf Centrifuge 5427 R to Their Product Portfolio 2Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 2Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 3Building 'invisible' materials with light 2
... 2012  Avaxia Biologics, Inc., a privately-held biotech company using ... for the treatment of gastrointestinal diseases, announced today that ... Officer of Arisaph Pharmaceuticals, Inc. to its Board of ... has agreed to serve on our Board," said Dr. ...
... Europe,s premier biotech conference continues to grow and see ... network which provides comprehensive support for bioscience businesses in ... announced the results of the sixth annual BioTrinity Biopartnering ... at Newbury Racecourse, UK, BioTrinity is now firmly established ...
... IRVINE, Calif., April 25, 2012 Aviir Diagnostic ... a contractual agreement with MultiPlan, Inc. for ancillary ... in the MultiPlan, PHCS and PHCS Savility Networks. ... cardiologists and scientists from the Stanford University School ...
Cached Biology Technology:Avaxia Biologics Elects Christopher Kiritsy to its Board of Directors 2Another Record Year for BioTrinity 2Another Record Year for BioTrinity 3Aviir Laboratories Announce National Agreement With MultiPlan 2
(Date:7/29/2014)... different types of cell, including sperm, bacteria and ... flagella. These protrusions, about one-hundredth of a millimetre ... through fluid. Similar, shorter structures called cilia are ... they perform roles such as moving liquids over ... remarkably versatile: they transport mucus and expel pathogens ...
(Date:7/28/2014)... 100 drugs already approved by the U.S. Food and ... the growth of certain bacterial pathogens inside human cells, ... spotted fever. The findings, published in mBio , ... Microbiology, demonstrate a new way of identifying non-antibiotic drugs ... , A handful of drugs on the list inhibit ...
(Date:7/28/2014)... Norwegian explorer Roald Amundsen reached the South Pole in ... arrived long before any human. , Using data from ... the Antarctic continent, including the South Pole, a group ... (DRI) in Reno, Nevada, created the most accurate and ... southernmost continent. The new record, described in an article ...
Breaking Biology News(10 mins):Microscopic rowing -- without a cox 2Microscopic rowing -- without a cox 3New route to identify drugs that can fight bacterial infections 2Lead pollution beat explorers to South Pole, persists today 2Lead pollution beat explorers to South Pole, persists today 3
... Oct. 25, 2012 /PRNewswire-iReach/ -- New research shows that ... Maine have demonstrated improvements in health behaviors that persisted ... and rising health care costs continue to challenge employers, ... to reduce health risks and improve health behaviors. ...
... provide the ideal petri dish for cultivating bioscience with ... so, given the opportunity to translate public funding into ... by UCSF researchers. In an analysis published Oct. ... at the California Institute for Quantitative Biosciences (QB3) assessed ...
... Risks of Overfishing," published today in the journal ... the Institute for Ocean Conservation Science and professor at ... According to Dr. Pikitch, current and recent studies demonstrate ... management, in which fishing is restricted to those places ...
Cached Biology News:New Study Shows That Improvements in Employee Health Behaviors Persist Over Two Years 2Academia should fulfill social contract by supporting bioscience startups, case study says 2Academia should fulfill social contract by supporting bioscience startups, case study says 3Traditional fisheries management approach jeopardizes marine ecosystems worldwide 2
CleanBox DNA workstation with two 254nm UV lambs & 12-hr timer, 90cm (36-inch)width, single door, 115V (w/crating)...
Mouse polyclonal antibody raised against a partial recombinant DDEF2. NCBI Entrez Gene ID = 8853...
Mouse polyclonal antibody to BAG2 - BCL2-associated athanogene 2...
... are multi-functional mixing devices. Stepping motors device ... solid, heavy-duty durable shaker to provide a ... vortexing in nature. Regulated action scale for ... display to control time, continuous time, action ...
Biology Products: